Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Could Moderna and AstraZeneca's mRNA Heart Failure Drug Candidate Be a Winner?

TheMotleyFool

0 0

Could Moderna and AstraZeneca's mRNA Heart Failure Drug Candidate Be a Winner?

Moderna (NASDAQ: MRNA) and AstraZeneca (NASDAQ: AZN) compete against each other in some markets with their respective COVID-19 vaccines. However, the two companies are also partners. They recently reported results from a phase 2 study of a messenger RNA (mRNA) heart failure drug. In this Motley Fool Live video recorded on Nov. 16, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Moderna's and AstraZeneca's mRNA candidate could be a winner.

Source Fool.com

Like: 0

MRNA

Share